Premium
Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single‐center, randomized, double‐blinded, placebo‐controlled clinical trial on M exican patients (skin type III – IV )
Author(s) -
TiradoSánchez Andrés,
Espíndola Yareni Salas,
PonceOlivera Rosa María,
Bonifaz Alexandro
Publication year - 2013
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12031
Subject(s) - adapalene , medicine , tretinoin , acne , dermatology , placebo , irritation , clinical trial , benzoyl peroxide , retinoic acid , pathology , chemistry , biochemistry , alternative medicine , organic chemistry , immunology , polymerization , gene , polymer
Summary Background The efficacy of topical retinoids is well known according to several clinical studies conducted predominantly among C aucasian patients. This study aimed to evaluate the efficacy and safety profile of adapalene and tretinoin among M exican patients. Aims To compare adapalene 0.1 and 0.3% and tretinoin 0.05% in M exican subjects with acne vulgaris. Methods We enrolled 171 patients in this single‐center, randomized, double‐blinded, placebo‐controlled clinical trial. The patients applied on the face either adapalene 0.1%, adapalene 0.3%, tretinoin 0.05%, or placebo for 90 days and were evaluated for the reduction in total lesion counts and for the level of irritation. Results Tretinoin 0.05% and adapalene 0.3% were more effective than adapalene 0.1% and placebo in the reduction of both inflammatory and noninflammatory lesions. Most of adverse events to adapalene and many on tretinoin group were related to skin irritation, dry skin, scaling, pruritus, burning, and postinflammatory hyperpigmentation. Conclusion Adapalene 0.3% and tretinoin 0.05% are comparable in efficacy, and adapalene 0.1% offers a better safety profile in M exican patients.